Our results suggest that even though DRG2 depletion enhanced the PD-L1 level in cancer cells, it inhibits the endosomal trafficking of PD-L1 and decreases the PD-L1 level on the surface of cancer cells, which results in poor response to anti-PD-1 therapy. The gene discussed is CD274; the disease is cancer.